What does “tafamidis patency” mean?
“Tafamidis” is a medicine used for certain forms of transthyretin amyloidosis. “Patency” usually refers to whether a drug is still protected by patents/exclusivity (for example, whether competitors can make or sell a generic or biosimilar). So “tafamidis patency” most often means the status of patent and exclusivity protection for tafamidis.
When does tafamidis patent/exclusivity protection expire?
DrugPatentWatch.com tracks patent and exclusivity events for medicines. You can check tafamidis’ current listed protection end dates and any patent “patency” risks (such as challenges or earlier-than-expected expiration) there: https://www.drugpatentwatch.com/
Has tafamidis had patent challenges or generics discussed?
Patent “patency” can change if a generic/biosimilar maker challenges a patent, or if a court ruling narrows/invalidates protection. For the most current litigation and competitor activity tied to tafamidis’ patent estate, DrugPatentWatch.com is a practical place to verify updates: https://www.drugpatentwatch.com/
What should you check if you want the exact “patency” date for your market?
Patent/exclusivity timelines can differ by country and by product form/strength (and sometimes by whether the question is about composition-of-matter patents vs. market exclusivity). To get the right “patency” answer, you typically need:
- the country (US, EU, UK, etc.)
- the specific tafamidis product (and whether you mean tafamidis meglumine vs. tafamidis free acid, where applicable)
- whether you mean patent expiry or regulatory exclusivity expiry
If you tell me the country and the exact tafamidis product (or the wording you saw), I can narrow the answer to the relevant patency/exclusivity window.
Quick check: what do you mean by “patency”?
Some sources use “patency” to mean something clinical (like blood-flow “patency”), but that would be unusual for tafamidis unless a specific study or indication is involved. If your question came from a clinical context (echo findings, vascular patency, access patency, etc.), share the sentence or source and I’ll interpret it correctly.
Sources
- DrugPatentWatch.com – Tafamidis patent and exclusivity monitoring